https://www.selleckchem.com/pr....oducts/ici-118551-ic
CCH efficacy/safety was assessed at baseline, days 22, 43, 71, and quarterly at day 360. Of the 259 OLE participants, 53 were observed for long-term CCH durability. For those who were ≥2-level composite responders during RCT (≥2-point CR-PCSS/PR-PCSS score improvements), CCH effect was durable (scores did not reach RCT baseline levels) in all women on days 180 (19/19), 360 (16/16), and 720 (7/7). Of the 200 women receiving CCH treatment/retreatment, more than 75% had ≥1-level improvement in patient and clinical assessment
Like
Comment
Share
